Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Allergy Therapeutics plc (AGYTF)
Worthing, GB
Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes prescription medications specifically designed to address pollen-related allergies, such as those caused by grasses, weeds, and trees, along with various diagnostic tools. Key products in their portfolio feature names like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Pollinex, VLP Peanut, and Penicillin diagnostics. Furthermore, Allergy Therapeutics is actively developing new allergy vaccines targeting a range of allergens, including trees, grass, house dust mites, animal dander, and peanuts. The company operates extensively across Central Europe, Southern Europe, the United Kingdom, and extends its market presence internationally. Established in 2004, Allergy Therapeutics plc is based in Worthing, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +29.41% | -37.14% | +5,689.47% | -75.56% | -45.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+36.9% ★ Q4'25: +8.0% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+21.5% ★ Q4'25: +34.5% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-73.9% Q4'25: -40.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-61.0% Q4'25: -32.9% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-1,205.2% Q4'25: -227.9% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+27.3% Q4'25: +92.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.49× Q4'25: -0.69× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
43.23M
est: 43.00M (+0.5%)
|
48.51M
est: 48.65M (-0.3%)
|
64.14M
est: 64.00M (+0.2%)
|
68.35M
est: 69.17M (-1.2%)
|
73.72M
est: 74.21M (-0.7%)
|
78.20M
est: 77.52M (+0.9%)
|
84.33M
est: 84.31M (+0.0%)
|
72.77M
est: 72.98M (-0.3%)
|
59.59M
est: 61.12M (-2.5%)
|
55.20M
est: 55.13M (+0.1%)
|
75.56M
est: 55.03M (+37.3%)
|
61.62M
61.62M – 61.62M
+12.0% YoY
|
252.95M
252.95M – 252.95M
+310.5% YoY
|
| EBITDA |
2.17M
est: -14.53M (+114.9%)
|
-10.56M
est: -16.44M (+35.8%)
|
191.0K
est: -21.63M (+100.9%)
|
-4.56M
est: -23.38M (+80.5%)
|
6.58M
est: -25.08M (+126.3%)
|
12.49M
est: -26.20M (+147.7%)
|
8.28M
est: -28.49M (+129.1%)
|
-7.82M
est: -24.67M (+68.3%)
|
-35.10M
est: -20.66M (-69.9%)
|
-30.74M
est: -18.63M (-65.0%)
|
-40.40M
est: -18.60M (-117.2%)
|
-20.83M
-20.83M – -20.83M
-12.0% YoY
|
-85.49M
-85.49M – -85.49M
-310.5% YoY
|
| EBIT |
872.0K
est: -17.38M (+105.0%)
|
-11.77M
est: -19.66M (+40.1%)
|
-1.75M
est: -25.87M (+93.3%)
|
-6.58M
est: -27.96M (+76.5%)
|
4.49M
est: -30.00M (+115.0%)
|
8.58M
est: -31.33M (+127.4%)
|
4.15M
est: -34.08M (+112.2%)
|
-11.99M
est: -29.50M (+59.4%)
|
-39.33M
est: -24.71M (-59.2%)
|
-35.06M
est: -22.29M (-57.3%)
|
-46.13M
est: -22.25M (-107.4%)
|
-24.91M
-24.91M – -24.91M
-12.0% YoY
|
-102.25M
-102.25M – -102.25M
-310.5% YoY
|
| Net Income |
108.0K
est: -2.21M (+104.9%)
|
-13.07M
est: -43.41M (+69.9%)
|
-2.48M
est: -12.67M (+80.4%)
|
-7.53M
est: -35.31M (+78.7%)
|
3.47M
est: -12.42M (+127.9%)
|
7.06M
est: 9.79M (-27.9%)
|
2.89M
est: 2.36M (+22.3%)
|
-13.78M
est: -37.76M (+63.5%)
|
-43.07M
est: -114.33M (+62.3%)
|
-40.22M
est: -47.61M (+15.5%)
|
-55.09M
est: -34.34M (-60.4%)
|
-32.64M
-32.64M – -32.64M
+5.0% YoY
|
42.92M
42.92M – 42.92M
+231.5% YoY
|
| SGA |
27.28M
est: 28.23M (-3.4%)
|
30.32M
est: 31.94M (-5.1%)
|
40.67M
est: 42.02M (-3.2%)
|
42.68M
est: 45.41M (-6.0%)
|
44.59M
est: 48.72M (-8.5%)
|
44.48M
est: 50.89M (-12.6%)
|
45.87M
est: 55.35M (-17.1%)
|
46.83M
est: 47.91M (-2.3%)
|
48.88M
est: 40.13M (+21.8%)
|
42.38M
est: 36.19M (+17.1%)
|
38.29M
est: 36.13M (+6.0%)
|
40.46M
40.46M – 40.46M
+12.0% YoY
|
166.06M
166.06M – 166.06M
+310.5% YoY
|
| EPS |
0.00
est: 0.00 (+122.6%)
|
-0.01
est: -0.01 (-54.1%)
|
0.00
est: 0.00 (+7.2%)
|
-0.01
est: -0.01 (-3.4%)
|
0.00
est: 0.00 (+222.1%)
|
0.01
est: 0.00 (+206.9%)
|
0.00
est: 0.00 (+485.8%)
|
-0.01
est: -0.01 (-51.5%)
|
-0.04
est: -0.02 (-56.8%)
|
-0.01
est: -0.01 (-7.1%)
|
-0.01
est: -0.01 (-16.6%)
|
-0.01
-0.01 – -0.01
+5.0% YoY
|
0.01
0.01 – 0.01
+231.5% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Manuel Llobet | Chief Executive Officer & Executive Director | 678.6K | male |
| Shaun Antony Furlong | Chief Financial Officer & Executive Director | 422.5K | male |
| Karley Charlotte Mouatt Cheesman | Company Secretary | — | female |
| Matthew Heath | Principal Scientist | — | male |
| Murray Skinner | Chief Scientific Officer | — | — |
| Russell Picket | Group Financial Controller | — | male |
| Simon Piggott | Head of Clinical Science | — | — |
| Alan Bullimore | Head of Communication & Market Development | — | male |
| Sue Baker | Head of Human Resources | — | female |
| Helge Weiner-Trapness | Chief Strategy Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AGYTF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
